Drug Profile
Research programme: factor Xa variants - Wyeth
Alternative Names: FXa-I16L; FXa-V17ALatest Information Update: 28 Sep 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Class Proteins
- Mechanism of Action Blood coagulation factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haemophilia
Most Recent Events
- 15 Oct 2009 Wyeth has been acquired by Pfizer